FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62596
News■ Mixed
NeuroSense Provides Update on Nasdaq Listing Compliance
KINDNews
DIRECTION■ Mixed
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 20:15 UTC
LAST UPDATE2026-10-02 20:15 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Regained bid-price compliance but still short of market-value requirement, so delisting risk persists pending a hearings panel.
Listing status partially fixed, overhang unresolved
CATALYST TO WATCH
Nasdaq hearings panel decision
MAIN RISK
Delisting if market value not regained
FULL DISPATCH
Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTNasdaq Composite · ^IXIC
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares ^IXIC
Nasdaq Adds 319 Points as Rate-Hike Odds Ebb: Stock Market Today2026-10-02 20:08 UTC
Nasdaq Adds 319 Points as Rate-Hike Odds Ebb: Stock Market Today2026-10-02 20:08 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
Finance Watch: Biopharmas Maintain Strong First-Day, Post-IPO Momentum2026-10-02 17:47 UTC
Finance Watch: Biopharmas Maintain Strong First-Day, Post-IPO Momentum2026-10-02 17:47 UTC
←CORRELATIONshares Healthcare
Rice Biotech Launch Pad invents 'living pharmacy' designed to produce therapeutics inside the body2026-10-02 18:01 UTC
Rice Biotech Launch Pad invents 'living pharmacy' designed to produce therapeutics inside the body2026-10-02 18:01 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.